CRP and type 2 diabetes mellitus: The potential reduction in the annual number of complications and their associated disability-adjusted life years (DALYs) and costs were estimated for reductions of 1% HbA1c, 5% weight and 0.5 mg/L hs-CRP in three T2D patient subgroup scenarios.